---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-013088"
form_type: "8-K"
ticker: "MAIA"
cik: "0001878313"
company_name: "MAIA Biotechnology, Inc."
filed_at: "2026-03-27T23:59:59+00:00"
generated_at: "2026-05-15T08:42:01.775582+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# MAIA presents THIO-101 data at ELCC showing sustained response in relapsed NSCLC

## Summary
- Poster presented at European Lung Cancer Congress 2026 in Copenhagen on March 27, 2026.
- Data from THIO-101 trial: Ateganosine + ICI in relapsed NSCLC patients.
- Poster title indicates sustained response and long-term therapeutic benefits after treatment cessation.
- No financial or numerical efficacy data disclosed in the 8-K; poster available on company website.

## SEC filing metadata
- accession: 0001493152-26-013088
- form_type: 8-K
- ticker: MAIA
- cik: 0001878313
- company_name: MAIA Biotechnology, Inc.
- filed_at: 2026-03-27T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1878313/000149315226013088/0001493152-26-013088-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1878313/000149315226013088/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-013088
- JSON: https://secwatch.observer/filing/0001493152-26-013088.json
- Plain text: https://secwatch.observer/filing/0001493152-26-013088.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.